Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cetoquagene Parvec

Vaccine (Adenoviral vector) · Gene replacement · developed by MeiraGTx, LLC

Phase 1 Most advanced trial (none active)
MGTX Developer
1 Registered trials

What is Cetoquagene Parvec?

Cetoquagene parvec is a replication-deficient recombinant adenovirus gene therapy encoding human aquaporin-1, a water channel protein. After transfection of salivary glands, it directs hAQP1 expression in the membranes of salivary secretory cells, which may increase saliva production. It is studied in head and neck cancer and in radiation-induced xerostomia and salivary hypofunction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AAV2hAQP1
Drug type
Vaccine (Adenoviral vector)
Mechanism
Gene replacement
Pathways
water transport across salivary secretory cell membranes, saliva production
Therapy area
Oncology
Developer
MeiraGTx, LLC (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
JXQ6DJ9TW6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02446249 Phase 1 Squamous Cell Head and Neck Cancer Completed MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Radiation Induced XerostomiaSalivary HypofunctionSquamous Cell Head and Neck Cancer

More from MeiraGTx, LLC

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind Cetoquagene Parvec

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.